-
Product Insights
NewComplement Factor H – Drugs In Development, 2024
The Complement Factor H pipeline drugs market research report outlays comprehensive information on the Complement Factor H targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genito Urinary System, Ophthalmology, and Immunology which include indications of Oncology, Breast Cancer, Kidney Disease (Nephropathy), Geographic Atrophy, Choroidal Neovascularization, Autoimmune Disorders, and Chronic Inflammation. It also reviews key players involved...
-
Product Insights
NewProstaglandin G/H Synthase 2 – Drugs In Development, 2024
The Prostaglandin G/H Synthase 2 pipeline drugs market research report outlays comprehensive information on the Prostaglandin G/H Synthase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Immunology, Musculoskeletal Disorders, and Oncology which include indications of Pain, Post-Operative Pain, Inflammation, Rheumatoid Arthritis, Osteoarthritis, Muscle Spasm, Solid Tumor, and Non-Small Cell Lung Cancer. It also...
-
Product Insights
NewProstaglandin G/H Synthase 1 – Drugs In Development, 2024
The Prostaglandin G/H Synthase 1 pipeline drugs market research report outlays comprehensive information on the Prostaglandin G/H Synthase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Immunology, Musculoskeletal Disorders, and Cardiovascular which include indications of Pain, Post-Operative Pain, Inflammation, Rheumatoid Arthritis, Osteoarthritis, Muscle Spasm, Patent Ductus Arteriosus, and Myocardial Infarction. It also reviews...
-
Innovation Ranking
Innovation Ranking – H. Lundbeck AS
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, migraine, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – H-3B6527 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - H-3B6527 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. H-3B6527 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: H-3B6527...
-
Innovation Ranking
Innovation Ranking – H&R Block Inc
H&R Block Inc (H&R Block) is a provider of consumer tax services worldwide. It offers tax return preparation services through professional tax preparers in company-owned and franchise retail tax offices; and provide H&R Block tax software products for the Do-It-Yourself (DIY) consumer. It Offers DIY products through channels such as in-person, online and mobile applications, and desktop software. It also offers services such as refund transfers, emerald advance line of credit, emerald prepaid MasterCard, extended service plan, tax identity shield,...
-
Innovation Ranking
Innovation Ranking – H & M Hennes & Mauritz AB
H & M Hennes & Mauritz AB (H&M) is a retailer of fashion apparel and accessories. The company’s products portfolio includes shorts, cardigans, sweaters, blazers suits, t-shirts, sweatshirts, shirts, sports and swimwear, lingerie. It also offers cosmetics and accessories such as jewelry, hats and gloves, belts and suspenders, home textiles, homeware, sunglasses, and watches. The company offers these products under H&M, Afound, COS, Monki, Weekday, Sellpy, Arket and & Other Stories brand names. H & M also sells its products...
-
Innovation Ranking
Innovation Ranking – Washington H Soul Pattinson and Co Ltd
Washington H Soul Pattinson and Co Ltd (WHSP) is a diversified investment company. WHSP holds interests in coal mining, copper mining and refining, property investments and consulting. It also invests in pharmaceutical and building products manufacturing companies. WHSP through its subsidiaries, explores, develops, mines and processes coal, oil, gas, copper and gold. It also invests in properties and financial instruments such as hybrid instruments, equities, derivatives and loans. The company serves its products and services to various sectors such as...
-
Product Insights
NewHereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2024
Empower your strategies with our Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2024 report and make more profitable business decisions. Hereditary inclusion body myopathy (h-IBM) is a rare, adult-onset muscle disorder. It is characterized by severe, progressive muscle weakness. Symptoms of IBM vary, but usually include progressive weakness in the muscles of the hand, forearm, thigh, and lower leg. Physical examination and medical history, blood tests to look for disease-specific enzymes or antibodies, nerve conduction studies to measure any...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – H-3B6527 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - H-3B6527 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. H-3B6527 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: H-3B6527 is...